Esteve Quimica
Esteve Quimica is a Spain-based pharmaceutical CDMO that develops and manufactures small molecule APIs, High Potent APIs, and pharmaceutical intermediates for pharmaceutical and biotechnology companies. Founded in 1929, it operates manufacturing facilities in Spain, Mexico, China, and the USA with 1,500+ employees.
- Company typePrivate
- Founded1929
- HeadquartersBarcelona, Spain
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Esteve Quimica does
Esteve Quimica is a Spain-headquartered pharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in small molecule Active Pharmaceutical Ingredients (APIs), High Potent APIs (HPAPIs), and advanced pharmaceutical intermediates. Founded in 1929 and headquartered in Barcelona, the company serves pharmaceutical and biotechnology companies through tailor-made contract manufacturing solutions spanning the full lifecycle from initial API development through on-market commercial product manufacturing. The company has manufactured APIs for highly regulated markets for more than 50 years and is regularly inspected by major Health Authorities, supporting a positioning of regulatory-grade quality compliance as a core capability.
The integrated service offering covers R&D, API/HPAPI manufacturing, technology platforms, project management, and an HSE Reliability layer that includes Global Quality Compliance, CMC Regulatory Services, Regulatory Status management, and Supply Chain Assurance. Manufacturing operations are distributed across four countries (Spain, Mexico, China, and the USA), with commercial presence extending across eight European markets (Benelux, France, Germany, Italy, Portugal, Spain, UK, and Catalonia). The company employs more than 1,500 people globally and holds B Corp certification. Revenue is generated through quote-based, multi-year contract manufacturing engagements negotiated on a per-project basis according to scale, complexity, and customer requirements. Go-to-market is direct enterprise field sales targeting pharmaceutical and biotechnology accounts, with the company explicitly framing its commercial model around long-term partnerships rather than transactional relationships.
Esteve Quimica firmographics
Firmographics- Name
- Esteve Quimica
- Legal name
- Esteve Quimica
- Website
- https://estevequimica.com
- Company type
- Private
- Founded year
- 1929
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Esteve Quimica is a Spain-based pharmaceutical CDMO that develops and manufactures small molecule APIs, High Potent APIs, and pharmaceutical intermediates for pharmaceutical and biotechnology companies. Founded in 1929, it operates manufacturing facilities in Spain, Mexico, China, and the USA with 1,500+ employees.
- Ownership category
- akta.pro rank
Esteve Quimica industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Small-Molecule API Commercial Manufacturing (HLAGAHAB), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Esteve Quimica is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices5 records
Markets served
Esteve Quimica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- CDMO Contract Manufacturing Services: Contract Development and Manufacturing Organization (CDMO) services providing tailor-made manufacturing solutions for the healthcare industry. They develop and manufacture small molecules APIs, High Potent APIs, and pharmaceutical intermediates. Revenue generated through long-term contract manufacturing partnerships with pharmaceutical and biotechnology companies, from R&D stages through commercial production.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based contract manufacturing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Esteve Quimica product offering
Product offeringCore offering
Esteve Quimica operates as a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule Active Pharmaceutical Ingredients (APIs), High Potent APIs (HPAPIs), and advanced pharmaceutical intermediates for pharmaceutical and biotechnology companies. The company delivers tailor-made manufacturing solutions spanning from early-stage API R&D through to commercial-scale production for highly regulated markets.
Product overview
Esteve Quimica operates as a Contract Development and Manufacturing Organization (CDMO) providing a comprehensive, integrated suite of pharmaceutical manufacturing services. The core offering is their CDMO Business, which encompasses R&D services, API/HPAPI/pharmaceutical intermediate manufacturing, technologies, and project management—all focused on long-term partnerships with pharmaceutical and biotechnology companies. Supporting the manufacturing operations are HSE Reliability services (Global Quality Compliance, CMC Regulatory Services, Regulatory Status, and Supply Chain Assurance), facilities across Spain, Mexico, China, and the USA, and organizational metrics tracked through CDMO by Numbers. The company has manufactured APIs for highly regulated markets for over 50 years with over 1,500 employees.
Differentiator
Problem solved
Functional benefit
Products and services
- Contract Development and Manufacturing Organization (CDMO) Services
Companies that use Esteve Quimica
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Esteve Quimica technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Esteve Quimica partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Partnering & Alliancesnot specifiedEsteve maintains a Partnering & Alliances section on their website, indicating active engagement in partnerships within the pharmaceutical industry. Specific partner names are not disclosed in the available source material.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Esteve Quimica competitors and assessment
Company assessmentDirect peers
- Recipharm: Recipharm is a European-headquartered CDMO providing small-molecule API and finished dosage form manufacturing services to pharma and biotech customers, with a comparable B2B contract manufacturing model and overlapping customer profiles.
- Aenova Group: Aenova is a European CDMO focused on solid, semi-solid, and liquid dosage forms as well as API manufacturing, with similar long-term partnership GTM and pharma/biotech customer base as Esteve.
- Fareva: Fareva is a privately held European CDMO with API and finished dose manufacturing capabilities serving global pharma customers, with comparable scale, multi-site footprint, and long-term contract manufacturing business model.
- Alcami Corporation: Alcami is a US-based CDMO offering small-molecule API development and manufacturing, sterile and oral finished dosage forms, and analytical services to pharma and biotech, directly comparable as a mid-sized API CDMO competitor.
- Siegfried Holding: Siegfried is a Swiss-headquartered CDMO specializing in small-molecule APIs and intermediates, including HPAPI capabilities, with a multi-site global manufacturing footprint, closely matching Esteve's core service offering and customer base.
- Cambrex: Cambrex is a leading small-molecule API CDMO offering development and manufacturing services to pharmaceutical and biotech customers across the full lifecycle, directly comparable to Esteve's small-molecule API, HPAPI, and intermediates offering with similar regulatory positioning.
Broad incumbents
- Lonza Group: Lonza is the largest global CDMO with broad capabilities across small molecules, biologics, and cell/gene therapies, representing the broad incumbent scale player against which Esteve competes for small-molecule and HPAPI projects.
- Catalent: Catalent is a large global CDMO providing development and manufacturing across multiple modalities including small molecules, biologics, and softgel, competing for large pharma contracts and setting market pricing benchmarks for the broader CDMO industry.
- Thermo Fisher Scientific (Patheon CDMO): Thermo Fisher's Patheon CDMO business offers end-to-end small-molecule API and finished dose services globally, representing a large incumbent peer whose scale and integration set competitive benchmarks for mid-sized European CDMOs like Esteve.
Regional players
- Eurofins CDMO (Amatsigroup): Eurofins' CDMO arm provides European-rooted small-molecule API and finished dosage form manufacturing with strong EU regulatory footprint, comparable in scope but more regionally focused than Esteve's global four-continent footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Esteve Quimica social profiles
Digital presenceEsteve Quimica compliance and trust
Trust signalCompliance2 records
Esteve Quimica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Esteve Quimica leadership team
Management profileNumber of profiles
Esteve Quimica funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Esteve Quimica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Esteve Quimica
What does Esteve Quimica do?
Esteve Quimica operates as a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures small molecule Active Pharmaceutical Ingredients (APIs), High Potent APIs (HPAPIs), and advanced pharmaceutical intermediates for pharmaceutical and biotechnology companies. The company delivers tailor-made manufacturing solutions spanning from early-stage API R&D through to commercial-scale production for highly regulated markets.
Is Esteve Quimica a public or private company?
Esteve Quimica is a private company. It is classified as family owned and is currently operating.
When was Esteve Quimica founded?
Esteve Quimica was founded in 1929. It employs 251 to 500 people.
Where is Esteve Quimica based?
Esteve Quimica is headquartered in Barcelona, Spain, in the Europe region.
How does Esteve Quimica make money?
One revenue line is on record: CDMO Contract Manufacturing Services.
Who are Esteve Quimica's main competitors?
Direct peers on record are Recipharm, Aenova Group, Fareva, Alcami Corporation, Siegfried Holding and Cambrex. Broad incumbents are Lonza Group, Catalent and Thermo Fisher Scientific (Patheon CDMO). Eurofins CDMO (Amatsigroup) is listed as a regional player.
Does Esteve Quimica have an API?
No public API is recorded for Esteve Quimica.
What industry is Esteve Quimica in?
Esteve Quimica's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 3254 and its SIC code is 2833.